ATHE logo

ATHEAlterity Therapeutics Ltd - ADR

$4.65
$0.24
(5.44%)
Today
Closed $4.65
$0.16
(3.44%)
After Hours
Updated: 07:57 PM EDT
Mkt Cap$1.69M
Vol39,654.00
News
all
press releases
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder
Alterity Therapeutics advances ATH434 toward Phase 3 after FDA alignment on trial design for MSA, while shares decline in premarket trading.read more...
Benzinga
News Placeholder
More News
News Placeholder
Alterity Therapeutics Gets Positive FDA Feedback On ATH434 Phase 3 Study
(RTTNews) - Alterity Therapeutics Limited (ATHE) on Monday said it received positive feedback from the U.S. Food and Drug Administration following a Type C meeting regarding its planned Phase 3 program for ATH434 in Multiple System Atrophy (MSA...
Nasdaq News: Markets
News Placeholder
Alterity Therapeutics Gains FDA Backing For Phase 3 MSA Trial
(RTTNews) - Alterity Therapeutics (ATHE, ATH.AX) announced that it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA...
Nasdaq News: Markets
News Placeholder
Alterity Therapeutics Announces Appointment Of Daniel Claassen As Chief Medical Advisor
(RTTNews) - Alterity Therapeutics Limited (ATHE), Wednesday announced the appointment of Daniel Claassen as Chief Medical Advisor, effective March 2026...
Nasdaq News: Markets
News Placeholder
Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars
A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.
Stocktwits
<
...
1
>